Antiatherogenic effect of pioglitazone on uremic apolipoprotein E knockout mice by modulation of the balance of regulatory and effector T cells

Atherosclerosis

Volumn 218, Issue 2, 2011, Pages 330-338

  Shen, Yan ^a   Yuan, Zuyi ^a   Yin, Aiping ^a   Liu, Yan ^a   Xiao, Yan ^a   Wu, Yue ^a   Wang, Lijun ^a   Liang, Xiao ^a   Zhao, Yan ^a   Tian, Yuling ^a   Liu, Weimin ^a   Chen, Tao ^a   Kishimoto, Chiharu ^b  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Effector T cells; Pioglitazone; PPAR ; Regulatory T cells; Uremia

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; APOLIPOPROTEIN E; CHOLESTEROL; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GELATINASE B; GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; OXIDIZED LOW DENSITY LIPOPROTEIN; PIOGLITAZONE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRIACYLGLYCEROL; UREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ROOT; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CHEMISTRY; BODY WEIGHT; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; DRUG EFFECT; EFFECTOR CELL; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; KIDNEY FUNCTION; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SPLEEN CELL; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; UREA NITROGEN BLOOD LEVEL; UREMIA;

ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BODY WEIGHT; CYTOKINES; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PPAR GAMMA; SPLEEN; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; THIAZOLIDINEDIONES; UREMIA;

EID: 84860421960     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.07.112     Document Type: Article

References (31)

1. Vanholder R., Massy Z., Argiles A., et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005, 20:1048-1056.
2. Leskinen Y., Lehtimäki T., Loimaala A., et al. Carotid atherosclerosis in chronic renal failure-the central role of increased plaque burden. Atherosclerosis 2003, 171:295-302.
3. Shik J., Parfrey P.S. The clinical epidemiology of cardiovascular disease in chronic kidney disease. Curr Opin Nephrol Hypertens 2005, 14:550-557.
4. Schiffrin E.L., Lipman M.L., Mann J.F. Chronic kidney disease effects on the cardiovascular system. Circulation 2007, 116:85-97.
5. Hansson G.K., Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006, 6:508-519.
6. Robertson A.K., Hansson G.K. T Cells in atherogenesis for better or for worse?. Arterioscler Thromb Vasc Biol 2006, 26:2421-2432.
7. Taleb S., Tedgui A., Mallat Z. Regulatory T-cell immunity and its relevance to atherosclerosis. J Intern Med 2008, 263:489-499.
8. Heller E.A., Liu E., Tager A.M., et al. Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T Cells. Circulation 2006, 113:2301-2312.
9. Xie J.J., Wang J., Tang T.T., et al. The Th17/Treg functional imbalance during atherogenesis in ApoE-/- mice. Cytokine 2010, 49:185-193.
10. Zhang J., Hua G., Zhang X., et al. Regulatory T cells/T-helper cell 17 functional imbalance in uraemic patients on maintenance haemodialysis: a pivotal link between microinflammation and adverse cardiovascular events. Nephrology (Carlton) 2010, 15:33-41.
11. Hendrikx T.K., van Gurp E.A., Mol W.M., et al. End-stage renal failure and regulatory activities of CD4+ CD25bright+ FoxP3+ T-cells. Nephrol Dial Transplant 2009, 24:1969-1978.
12. Duan S.Z., Usher M.G., Mortensen R.M. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Circ Res 2008, 102:283-294.
13. Nissen S.E., Nicholls S.J., Wolski K., et al. Comparison of pioglitazone vs. glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The PERISCOPE randomized controlled trial. JAMA 2008, 299:1561-1573.
14. Hontecillas R., Bassaganya-Riera J. Peroxisome proliferator-activated receptor gamma is required for regulatory CD4+ T cell-mediated protection against colitis. J Immunol 2007, 178:2940-2949.
15. Wohlfert E.A., Nichols F.C., Nevius E., Clark R.B. Peroxisome proliferator-activated receptor γ (PPARγ) and immunoregulation: enhancement of regulatory T cells through PPARγ dependent and independent mechanisms. J Immunol 2007, 178:4129-4135.
16. Gagnon R.F., Gallimore B. Characterization of a mouse model of chronic uremia. Urol Res 1988, 16:119-126.
17. Tian Y., Yuan Z., Liu Y., et al. Pioglitazone modulates the balance of effector and regulatory T cells in apolipoprotein E deficient mice. Nutr Metab Cardiovasc Dis 2011, 21:25-32.
18. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) method. Methods 2001, 25:402-408.
19. Lindner A., Charra B., Sherrard D.J., Scribner B.H. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974, 290:697-701.
20. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
21. Ivanovski O., Nikolov I.G., Joki N., et al. The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice. Atherosclerosis 2009, 205:55-62.
22. Gough P.J., Gomez I.G., Wille P.T., Raines E.W. Macrophage expression of active MMP-9 induce acute plaque disruption in apoE-deficient mice. J Clin Invest 2006, 116:59-69.
23. Meier P., Meier R., Blanc E. Influence of CD4+/CD25+ regulatory T cells on atherogenesis in patients with end-stage kidney disease. Expert Rev Cardiovasc Ther 2008, 6:987-997.
24. Meier P., Golshayan D., Blanc E., Pascual M., Burnier M. Oxidized LDL modulates apoptosis of regulatory T cells in patients with ESRD. J Am Soc Nephrol 2009, 20:1368-1384.
25. Sakaguchi S., Ono M., Setoguchi R., et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006, 212:8-27.
26. Ait-Oufella H., Salomon B.L., Potteaux S., et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006, 12:178-180.
27. Mor A., Luboshits G., Planer D., Keren G., George J. Altered status of CD4+ CD25+ regulatory T cells in patients with acute coronary syndromes. Eur Heart J 2006, 27:2530-2537.
28. de Boer O.J., van der Meer J.J., Teeling P., van der Loos C.M., van der Wal A.C. Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions. PLoS One 2007, 2:e779.
29. Mor A., Planer D., Luboshits G., et al. Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27:893-900.
30. Rosen E.D., Spiegelman B.M. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001, 276:37731-37734.
31. Nesto R.W., Bell D., Bonow R.O., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 2003, 108:2941-2948.